Group purchasing organizations and purchasing groups, affiliations, and coalitions
We realize that in healthcare, you can’t go it alone. It takes partners and associates coming together in collaboration to achieve efficient, cost-effective care for patients. We also understand the financial and operational pressures faced by today’s hospitals and healthcare systems, because we are a hospital too. Group purchasing organizations (GPOs) and purchasing groups (PGs) help hospitals by shouldering the burden of negotiating the best member pricing and benefits with quality suppliers. At Mayo Clinic Laboratories, we welcome the opportunity to serve members by establishing relationships with their GPOs and PGs to provide member access to our broad esoteric testing menu and services.
Building laboratory value
The financial pressure on hospitals continues. To help, we can support hospital laboratories by evaluating current utilization, capacity, and processes to help reduce waste, find efficiencies, and maximize capabilities for optimal financial performance.
We also offer support in building and expanding laboratory outreach programs. Our experienced, industry-leading outreach consultants offer unparalleled insights and experience to help hospital-based laboratories evolve from cost-centers to revenue generators. Learn more about how we can support laboratories’ optimization and revenue-generation goals.
Driving efficiency through consolidation
Most hospital laboratories find themselves sending tests to an increasing number of commercial and specialty reference laboratories. Managing the complexities of these various relationships increases operational burden, staff workload, and inconsistencies in testing methods and interpretation of results.
Hospitals and health systems can optimize their laboratory testing referrals by leveraging our extensive test menu, which includes advanced diagnostics, cutting-edge technology, and clinically relevant new tests across our full spectrum of medical subspecialties.
“The type of service we provide is really tailored to the needs of the hospital or to the healthcare system. And their patients are no different than the patients that walk through our doors.”
William Morice, M.D., Ph.D., CEO and President of Mayo Clinic Laboratories
Sharing knowledge and empowering staff
We support care teams by providing insights and education as they strive to solve the most complex medical challenges. Our education offerings range from conferences to on-demand programs to webinars — many of which offer CME credit. View our extensive educational offerings.
In addition, hospital and laboratory staff have direct access to Mayo Clinic physicians and scientists, who can help with optimizing test orders and interpreting results. Mayo Clinic Laboratories provides each client with a dedicated team of account, clinical, and laboratory technical professionals.
Prioritizing patient care
With guidance from our practicing physicians, we continuously develop testing algorithms, invest in research, and develop new tests so that patients have access to the best testing available. As a hospital-based reference laboratory, our focus is helping clients prevent overutilization of laboratory testing, drive efficiency through consolidation of send-out testing, and generate hospital revenue by establishing and growing lab outreach programs. And, we provide benefits only available through a connection with a world-class medical institution: access to our Mayo Clinic physicians and consultants, educational offerings, and the most cutting-edge, clinically-based testing available in the market.
News and updates
The latest
Join us Sept. 23–24, 2026, in Rochester, Minnesota, for our annual outreach conference. This year’s event, Leveraging the Laboratory: Bold Thinking. Big Impact., focuses on how innovative approaches and strategic decision-making can drive meaningful results for health system laboratory outreach programs.
This week's research roundup feature: VEXAS (Vacuoles, E1 enzyme, X-linked, Autoinflammatory, Somatic) syndrome, caused by somatic mutations in UBA1, is an autoinflammatory disorder with diverse systemic manifestations. Thrombosis is a prominent clinical feature of VEXAS. The risks factors and frequency of thrombosis in VEXAS are not well described, due to the disease's new discovery and paucity of large databases. We evaluated 119 VEXAS patients for venous and arterial thrombosis and correlated their presence with clinical outcomes and survival.
Prevented from providing testing services to its community members due to a non-compete agreement with a national laboratory, Kootenai Health laboratory leaders deepened their relationship with Mayo Clinic Laboratories, receiving tactical support and guidance to launch an in-house reference lab just days after the non-compete agreement expired.
David Murray, M.D., Ph.D., explains how Mayo Clinic Laboratories' MASSFIX Quantitation assay provides next-generation screening for M-proteins, which are associated with multiple myeloma and other diseases. The assay better quantitates the blood proteins, for improved patient care and simpler test ordering.
This week's research roundup feature: Powassan virus (POWV) is an emerging arthropod-borne flavivirus, transmitted by Ixodes spp. ticks, which has been associated with neuroinvasive disease and poor outcomes.
Multiple doctors and multiple examinations could not figure out why Lauri Sieben had spent much of her life “never feeling quite right” physically. Fortunately for Lauri, that changed after her daughter Christy began working as a genetic counselor in Mayo Clinic’s Molecular Technologies Laboratory. After seeing similarities between the patient testing she was performing for the lab and the physical symptoms being experienced by her mom, Christy took a leading role in getting Lauri to undergo molecular and biochemical testing at Mayo Clinic. The results of that testing not only provided much-needed answers, but a promising path forward for Lauri.
Staff retention is a critical factor in achieving organizational success, providing continuity, stability, and preserving institutional knowledge within a company.
In this episode of “Lab Medicine Rounds,” host Justin Kreuter, M.D., speaks with placement coordinator Jamie Herget to discuss recruitment initiatives within the laboratory profession.[...]
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, to discuss what companies in the healthcare and diagnostics industries are focusing on in 2024.
This page includes updates posted to Mayo Clinic Labs during the month of January.
Joshua Bornhorst, Ph.D., explains how Mayo Clinic Laboratories' unique assay identifies pregnant women at risk of developing preeclampsia with severe features. Test results can guide clinical management, to safeguard maternal and neonatal health.
Mayo Clinic Laboratories now offers the first preeclampsia-specific test (Mayo ID: PERA) that can be used to stratify patients into low or high-risk categories, indicating whether a patient is at risk for developing preeclampsia with severe features. With this information, clinicians can make more informed decisions about hospitalization, monitoring, more frequent checkups, and even early delivery.
This week's research roundup feature: Incapacitated regulatory T cells (Tregs) contribute to immune-mediated diseases. Inflammatory Tregs are evident during human inflammatory bowel disease (IBD); however, mechanisms driving the development of these cells and their function are not well understood. Therefore, we investigated the role of cellular metabolism in Tregs relevant to gut homeostasis.